Table 4.
Lorlatinib efficacy data among Japanese patients receiving alectinib as their only prior ALK TKI (cohort EXP3B)
| Patient | Agent for advanced/metastatic disease | Best response for lorlatinib | Progression‐Free Survival (months), ► (ongoing) | |||
|---|---|---|---|---|---|---|
| Regimen | Agent | BOR | Overall | Intracranial | ||
| 1 | 1 | Alectinib | PR | PR | No metastases |
 ► |
| 2 | Carboplatin | PR | ||||
| 2 | Bevacizumab | PR | ||||
| 2 | Pemetrexed | PR | ||||
| 2 | 1 | Cisplatin | NA a | PR | No metastases |
 ► |
| 1 | Pemetrexed | NA a | ||||
| 2 | Alectinib | PR | ||||
| 3 | Cisplatin | Unknown | ||||
| 3 | Pemetrexed | Unknown | ||||
| 3 | 1 | Bevacizumab | SD | CR | No metastases |
|
| 1 | Paclitaxel | SD | ||||
| 1 | Irinotecan | SD | ||||
| 2 | Alectinib | PR | ||||
| 4 | 1 | Cisplatin | PR | SD | No metastases |
|
| 1 | TS‐1 | PR | ||||
| 2 | Alectinib | PR | ||||
| 5 | 1 | Alectinib | SD | SD | No metastases |
|
| 2 | Cisplatin | PR | ||||
| 2 | Pemetrexed | PR | ||||
| 6 | 1 | Carboplatin | NA a | SD | No metastases |
|
| 1 | Paclitaxel | NA a | ||||
| 1 | Fluorouracil | NA a | ||||
| 2 | Bevacizumab | Unknown | ||||
| 2 | Carboplatin | Unknown | ||||
| 2 | Pemetrexed | Unknown | ||||
| 3 | Alectinib | PR | ||||
| 7 | 1 | Alectinib | PR | PD | No metastases |
|
Abbreviations: BOR, best overall response; CR, confirmed response; NA, not available; PD, progressive disease; PR, partial response, SD, stable disease/no response.
a
Adjuvant therapy only.